Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization
Common chronic diseases represent the greatest driver of rising healthcare costs, as well as declining function, independence, and quality of life. Geroscience‐guided approaches seek to delay the onset and progression of multiple chronic conditions by targeting fundamental biological pathways of agi...
Saved in:
Published in: | Aging cell Vol. 21; no. 4; pp. e13596 - n/a |
---|---|
Main Authors: | , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
John Wiley & Sons, Inc
01-04-2022
John Wiley and Sons Inc |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Common chronic diseases represent the greatest driver of rising healthcare costs, as well as declining function, independence, and quality of life. Geroscience‐guided approaches seek to delay the onset and progression of multiple chronic conditions by targeting fundamental biological pathways of aging. This approach is more likely to improve overall health and function in old age than treating individual diseases, by addressing aging the largest and mostly ignored risk factor for the leading causes of morbidity in older adults. Nevertheless, challenges in repurposing existing and moving newly discovered interventions from the bench to clinical care have impeded the progress of this potentially transformational paradigm shift. In this article, we propose the creation of a standardized process for evaluating FDA‐approved medications for their geroscience potential. Criteria for systematically evaluating the existing literature that spans from animal models to human studies will permit the prioritization of efforts and financial investments for translating geroscience and allow immediate progress on the design of the next Targeting Aging with MEtformin (TAME)‐like study involving such candidate gerotherapeutics.
Geroscience‐guided approaches seek to delay the onset and progression of chronic conditions by targeting the pathways of aging. This approach is likely to improve overall health in old age by addressing aging—the largest risk factor for the leading causes of morbidity. Here, we propose the creation of a standardized process for evaluating FDA‐approved drugs for their geroscience potential, permitting the prioritization of efforts and investments for translating geroscience discoveries. |
---|---|
Bibliography: | Ameya S. Kulkarni and Sandra Aleksic contributed equally to this work. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-2 |
ISSN: | 1474-9718 1474-9726 |
DOI: | 10.1111/acel.13596 |